Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TARA
PROTARA THERAPEUTICS, INC.
NASDAQ
$3.94
▼ DOWN 0.76% (-0.03)

KEY STATISTICS

Market Cap$221.44 M
52w High$7.82
52w Low$3.02
Dividend Yield—
Frequency—
P/E-2.94
Volume203.01K
Shares Out.56.20M

COMPANY

LEADERSHIP

Jesse Shefferman
CHIEF EXECUTIVE
Jesse Shefferman

COMPENSATION 2026

Salary$654,888
Stock Awards$294,450
Incentive Plan Pay$351,184
All Other Comp.$78,036
Total$2,655,774

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 22, 2014
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
46

PRICE TARGET

Target High$12.00
Target Low$12.00
Target Median$12.00
Target Consensus$12.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.—
NOV
9
MON

SPLIT RECORD

DATETYPERATIO
2020-01-10Reverse1:40

PRICE

$3.94 ▼ DOWN 0.76% (−$0.03)
OVERLAYS
$3.90$3.92$3.94$3.969:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM3.94

About Protara Therapeutics, Inc.

https://www.protaratx.com ↗

Protara Therapeutics, Inc. is a clinical-stage biopharma company developing innovative therapies for cancer and rare diseases, including TARA-002 for lymphatic malformations and choline chloride for liver disease, based in New York.

INDUSTRY

Biotechnology

A PRODUCT PROTARA THERAPEUTICS, INC. IS KNOWN FOR

IV Choline Chloride
IV Choline Chloride

IV Choline Chloride is an investigational intravenous therapy in Phase 3, developed to provide choline for long-term parenteral support patients, with potential to be the first FDA-approved IV choline treatment.

COMPETITORS

COMPETITOR
AMPH COMPARE
BAX COMPARE
GRFS COMPARE
ICUI COMPARE
PFE COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
54
LISTED HERE
11
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.7M
IWM
0.01% · 1.3M
DFMC
0.01% · 144.9K
R2SC.L
0.01% · 129.0K
AVSC
0.01% · 95.0K
SBIO
0.12% · 74.2K
XRS2.DE
0.01% · 53.1K
RSSL
0.01% · 24.8K
URTY
0.00% · 2.1K
PQ
PQSG
0.13% · 1.8K
SC0K.DE
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
54.78%
HOLDERS
164
TOP 12 OF 164 · RANKED BY POSITION SIZE
Janus Henderson Group Plc
5.2M sh · $27.15M
Blackrock, Inc.
3.7M sh · $13.99M
Millennium Management LLC
3.1M sh · $11.85M
Velan Capital Investment Management LP
2.8M sh · $10.87M
Vanguard Group Inc
2.4M sh · $12.75M
Blackstone Inc.
2.3M sh · $8.65M
Integral Health Asset Management, LLC
2.3M sh · $11.99M
Orbimed Advisors LLC
2.2M sh · $8.48M
Sio Capital Management, LLC
2.0M sh · $10.26M
Acorn Capital Advisors, LLC
1.8M sh · $9.34M
Aigh Capital Management LLC
1.6M sh · $8.45M
Catalio Capital Management, LP
1.5M sh · $6.53M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CEO AND PRESIDENT
Shefferman Jesse
Purchase · 215.7K shares
2026-06-29
★
DIRECTOR, OFFICER: CEO AND PRESIDENT
Shefferman Jesse
Sale · 14.0K shares
2026-06-30
★
DIRECTOR, OFFICER: CEO AND PRESIDENT
Shefferman Jesse
Sale · 7.0K shares
2026-06-30
★
DIRECTOR, OFFICER: CEO AND PRESIDENT
Shefferman Jesse
Sale · 4.0K shares
2026-06-30

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 1
OVERWEIGHT 1
BUY 1
3 GRADES IN THE LAST 12 MONTHS
Oppenheimer OUTPERFORM JP Morgan OVERWEIGHT HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
SLS$13.86COMPARE
OABI$4.33COMPARE
PRLD$5.46COMPARE
OBIO$5.08COMPARE
IVVD$0.83COMPARE
MDWD$13.29COMPARE
CDXS$1.46COMPARE
NTHI$5.03COMPARE